Waters will join several venture investors including, Floodgate Capital, First Round Capital, Underscore VC, Founder Collective, and Y Combinator, to invest in TetraScience’s $8-million series A round of financing.
TetraScience, a Boston, MA-based cloud technology company for life sciences R&D, announced on Oct. 31, 2019 it obtained a strategic investment from Waters, a specialty measurement company located in Milford, MA.
Waters will join several venture investors including, Floodgate Capital, First Round Capital, Underscore VC, Founder Collective, and Y Combinator, to invest in TetraScience’s $8-million series A round of financing, according to a press release. TetraScience will use the funding to develop its commercial team and its list of global customers and partners.
"We are honored by this vote of confidence from a renowned industry leader," said Siping (Spin) Wang, co-founder and CEO of TetraScience, in the press release. "Waters Corporation brings to the table [more than] 60 years of experience in high value analytical technologies, scientific expertise, and a global footprint. We look forward to working together to transform the future of R&D."
"We believe that dynamic, young companies like TetraScience have an enabling role to play in advancing the way the scientific community collects, shares, and analyzes R&D data," added Alan Millar, senior director of Corporate Development for Waters, in the press release. "Waters is excited to support TetraScience via this investment."
Source: TetraScience
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.